Every year NIH alone awards over $120,000,000 via R’-Mechanisms, among them the RO1 or R21. In order to maximize your funding potential all sources of funding must be considered including the less traditional sources. R21s aim to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas […]
The National Institute of Allergy and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA, etc. this is a funding force no one in the field can afford to ignore. Date: Wednesday, July 16 Time: 12:00 – 1:00 PM, EDT In this first webinar in the […]
Weekly Online Educational Webinars – July 2nd – August 27th, 2014 FreeMind’s knowledgeable team of expert grant writers share their wisdom on how to maximize chances for award. Participation is FREE of Charge, Registration is Required Date Title July 16th Biodefense and Infectious Diseases Non-dilutive Funding July 23rd RO1 and R21s for Companies July 30th […]
The FreeMind Group and CONNECT are pleased to invite you to a full day of non-dilutive funding activities on June 23rd at the Procopio Law offices – 525 B Street, Suite 2200 – Participation is FREE of charge Seating is limited, so please register in advance to reserve AGENDA Non-dilutive Funding During the BIO International […]
!NIH/DOD Non-dilutive Funding Opportunities; Non-US Applicants are Welcome Presenter: Ayal Ronen, Vice President, FreeMind Group Agenda: 9:00-09:30 Registration and networking breakfast 09:30-10:30 Presentation 10:30-10:45 Q&A 11:00-12:00 Meet the expert – 1X1 meetings with the FreeMind team REGISTRATION Presentation Outline Currently, the National Institutes of Health (NIH) are actively funding 1,124 projects amounting to $1.3B, taking […]
The FreeMind Group and the 9th Annual Non-Dilutive Funding Summit is proud to host Dr. Anthony Boccanfuso, Executive Director, The National Academies’ University-Industry Demonstration Partnership (UIDP) who will discuss in his presentation industry-academic collaborations and how the life science industry can leverage such ties to secure non-diltuive capital to fund their R&D activities. Following the […]
FreeMind Group and the 9th Annual Non-Dilutive Funding Summit are proud to host Dr. Larry Mahan of the National Heart, Lung, and Blood Institute (NHLBI; NIH) who will share her insight into the NHLBI’s interests and funding agenda, as well as the NIH funding opportunities and other resources available to the community that facilitate and […]
The 9th Annual Non-dilutive Funding Summit is proud to host Ram May-Ron, Managing Partner, FreeMind Group who will give a presentation on a “2014 Non-Dilutive Funding Forecast”. In his presentation Mr May-Ron will share his insight into Life Science funding trends and specifically non-dilutive funding as the driving force in this sector.
The purpose of this funding opportunity announcement (FOA) is to encourage applications to the newly authorized Direct-to-Phase II SBIR grant mechanism. Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, […]
Meet FreeMind at the Partnership in Clinical trials event in Las Vegas on March 30th to discuss sources of funding able to fund your clinical trial! For more than 22 years, Partnerships has been a cornerstone for thousands of clinical executives to partner, learn, and innovate. This coming year, we’re taking PCT to a whole […]